BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 25112436)

  • 21. YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.
    Xu Y; Lin H; Meng N; Lu W; Li G; Han Y; Dai X; Xia Y; Song X; Yang S; Wei Y; Yu L; Zhao Y
    Br J Pharmacol; 2013 Aug; 169(8):1766-80. PubMed ID: 23594209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Pang X; Yi Z; Zhang X; Sung B; Qu W; Lian X; Aggarwal BB; Liu M
    Cancer Res; 2009 Jul; 69(14):5893-900. PubMed ID: 19567671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
    Niu G; Sun L; Pei Y; Wang D
    Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Br J Pharmacol; 2014 Dec; 171(24):5728-42. PubMed ID: 25091695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
    Gao J; Hu H; Wang X
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.
    Liu Y; He Y; Yang F; Cong X; Wang J; Peng S; Gao D; Wang W; Lan L; Ying X; Liu M; Chen Y; Yi Z
    Sci China Life Sci; 2017 Feb; 60(2):202-214. PubMed ID: 28194552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
    Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
    Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling.
    Lu J; Zhang K; Nam S; Anderson RA; Jove R; Wen W
    Carcinogenesis; 2010 Mar; 31(3):481-8. PubMed ID: 19969552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation.
    Zhang YM; Dai BL; Zheng L; Zhan YZ; Zhang J; Smith WW; Wang XL; Chen YN; He LC
    Cell Death Dis; 2012 Oct; 3(10):e406. PubMed ID: 23059825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
    Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
    Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.
    Wang N; Wang ZY; Mo SL; Loo TY; Wang DM; Luo HB; Yang DP; Chen YL; Shen JG; Chen JP
    Breast Cancer Res Treat; 2012 Aug; 134(3):943-55. PubMed ID: 22350787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
    Xu HY; Pan YM; Chen ZW; Lin Y; Wang LH; Chen YH; Jie TT; Lu YY; Liu JC
    J Ethnopharmacol; 2013 Apr; 146(3):724-33. PubMed ID: 23434607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raddeanin A, a triterpenoid saponin isolated from Anemone raddeana, suppresses the angiogenesis and growth of human colorectal tumor by inhibiting VEGFR2 signaling.
    Guan YY; Liu HJ; Luan X; Xu JR; Lu Q; Liu YR; Gao YG; Zhao M; Chen HZ; Fang C
    Phytomedicine; 2015 Jan; 22(1):103-10. PubMed ID: 25636878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades.
    Lee JH; Choi S; Lee Y; Lee HJ; Kim KH; Ahn KS; Bae H; Lee HJ; Lee EO; Ahn KS; Ryu SY; Lü J; Kim SH
    Mol Cancer Ther; 2010 Feb; 9(2):389-99. PubMed ID: 20103598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
    Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
    Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Melanocyte-stimulating hormone inhibits angiogenesis through attenuation of VEGF/VEGFR2 signaling pathway.
    Weng WT; Huang SC; Ma YL; Chan HH; Lin SW; Wu JC; Wu CY; Wen ZH; Wang EM; Wu CL; Tai MH
    Biochim Biophys Acta; 2014 Jun; 1840(6):1850-60. PubMed ID: 24530634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.